CoChat

Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: Patients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased risk driven potentially by inflammation. Tumour necrosis factor inhibitors (TNFi) may modulate the risk and severity of MI. We compared the risk and severity of MI in patients treated with TNFi with that in those receiving synthetic disease-modifying antirheumatic drugs (sDMARDs). METHODS: This analysis included patients with RA recruited from 2001 to 2009 to the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis starting TNFi (etanercept/infliximab/adalimumab) and a biologic-naïve comparator cohort receiving sDMARD. All patients were followed via physician and patient questionnaires and national death register linkage. Additionally, all patients were linked to the Myocardial Ischaemia National Audit Project, a national registry of hospitalisations for MI. Patients were censored at first verified MI, death, 90 days following TNFi discontinuation, last physician follow-up or 20 April 2010, whichever came first. The risk of first MI was compared between cohorts using COX regression, adjusted with propensity score deciles (PD). MI phenotype and severity were compared using descriptive statistics. 6-month mortality post MI was compared using logistic regression. RESULTS: 252 verified first MIs were analysed: 58 in 3058 patients receiving sDMARD and 194 in 11 200 patients receiving TNFi (median follow-up per person 3.5 years and 5.3 years, respectively). The PD-adjusted HR of MI in TNFi referent to sDMARD was 0.61 (95% CI 0.41 to 0.89). No statistically significant differences in MI severity or mortality were observed between treatment groups. CONCLUSIONS: Patients with RA receiving TNFi had a decreased risk of MI compared with patients with RA receiving sDMARD therapy over the medium term. This might be attributed to a direct action of TNFi on the atherosclerotic process or better overall disease control.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2016-209784

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Patient selection for analysis. BSRBR-RA, British Society for Rheumatology Biologics Register for Rheumatoid Arthritis; DAS28, disease activity in 28 joints; DMARD, disease-modifying antirheumatic drug; MI, myocardial infarction; RA, rheumatoid arthritis; TNF, tumour necrosis factor.
Figure 1 Patient selection for analysis. BSRBR-RA, British Society for Rheumatology Biologics Register for Rheumatoid Arthritis; DAS28, disease activity in 28 joints; DMARD, disease-modifying antirheumatic drug; MI, myocardial infarction; RA, rheumatoid arthritis; TNF, tumour necrosis factor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 159

Metadata

Authors
Low, A. S. L., Symmons, D. P. M., Lunt, M., Mercer, L. K., Gale, C. P., Watson, K. D., Dixon, W. G., & Hyrich, K. L.
Affiliations
  • University of Manchester (GB)
  • Manchester Academic Health Science Centre (GB)
  • University of Leeds (GB)
Corresponding author
Hyrich, Kimme L
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2017-04
Volume
76
Issue
4
Pages
654-660
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2568758989
Cited by
158
References
36
Citations by year
2026: 3 · 2025: 10 · 2024: 12 · 2023: 21 · 2022: 14 · 2021: 17 · 2020: 20 · 2019: 30 · 2018: 21 · 2017: 9
FWCI
19.12
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of the Rheumatic Diseases (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion, cc-by)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
  • Medical Research Council (G0701380/1, G0902272)
  • Arthritis Research UK (20380)
  • National Institute for Health Research (NIHR-CTF-2014-03-03)
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
Keywords
rheumatoid arthritis, tumor necrosis factor inhibitors, myocardial infarction, cardiovascular risk, etanercept, infliximab, adalimumab, atherosclerosis, disease control
MeSH terms
Etanercept, Adalimumab, Infliximab, Adult, Aged, Arthritis, Rheumatoid, Female, United Kingdom, Humans, Male, Middle Aged, Myocardial Infarction, Severity of Illness Index, Tumor Necrosis Factor-alpha, Incidence, Antirheumatic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. https://app.cochat.ai/papers/10.1136/annrheumdis-2016-209784
The paper
Low, A. S. L., Symmons, D. P. M., Lunt, M., Mercer, L. K., Gale, C. P., Watson, K. D., Dixon, W. G., & Hyrich, K. L. (2017). Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2016-209784

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.